메뉴 건너뛰기




Volumn 17, Issue 2, 2008, Pages 110-114

The US drug safety system: Role of the pharmaceutical industry

Author keywords

Biotechnology industry; Drug safety; Institute of medicine; Pharmaceutical industry; Pharmacoepidemiology; Pharmacovigilance

Indexed keywords

DRUG;

EID: 39749147799     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1467     Document Type: Review
Times cited : (4)

References (15)
  • 3
    • 39749091857 scopus 로고    scopus 로고
    • Institute of Medicine. Testimony to the Committee on the Assessment of the U.S. Drug Safety System, Meeting Two, 19 July 2005, http://www.nclnet.org/advocacy/health/testimony_iom_07192005.htm (12 May 2006).
    • Institute of Medicine. Testimony to the Committee on the Assessment of the U.S. Drug Safety System, Meeting Two, 19 July 2005, http://www.nclnet.org/advocacy/health/testimony_iom_07192005.htm (12 May 2006).
  • 7
    • 39749183545 scopus 로고    scopus 로고
    • Final PDUFA recommendation transmitted to Congress will strengthen drug review and drug safety
    • 23 March, 06 June
    • U.S. Food and Drug Administration. Final PDUFA recommendation transmitted to Congress will strengthen drug review and drug safety. FDA News 23 March 2007, http://wwww.fda.gov/bbs/topics/NEWS/2007/ NEW01592.html (06 June 2007).
    • (2007) FDA News
  • 8
    • 9644260609 scopus 로고    scopus 로고
    • Potential for conflict of interest in the evaluation of suspected adverse drug reactions: Use of cerivastatin and risk of rhabdomyolysis
    • DOI:10.1001/jama.292.21.2622
    • Psaty BM, Furberg CD, Ray WA, Weiss NS. Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis. JAMA 2004; 292: 2622-2631. DOI:10.1001/jama.292.21.2622
    • (2004) JAMA , vol.292 , pp. 2622-2631
    • Psaty, B.M.1    Furberg, C.D.2    Ray, W.A.3    Weiss, N.S.4
  • 9
    • 23044447801 scopus 로고    scopus 로고
    • Opening Pandora's pillbox: Using modern information tools to improve drug safety
    • DOI: 10.1377/hlthaff.24.4.938
    • Gottlieb S. Opening Pandora's pillbox: using modern information tools to improve drug safety. Health Aff 2005; 24: 938-948. DOI: 10.1377/hlthaff.24.4.938
    • (2005) Health Aff , vol.24 , pp. 938-948
    • Gottlieb, S.1
  • 10
    • 0040182608 scopus 로고    scopus 로고
    • Monitoring medications in the marketplace: The centers for education and research have small budgets, but big goals
    • Hart C. Monitoring medications in the marketplace: the centers for education and research have small budgets, but big goals. Mod Drug Discov 2000; 3(5): 40-44.
    • (2000) Mod Drug Discov , vol.3 , Issue.5 , pp. 40-44
    • Hart, C.1
  • 11
    • 33645282249 scopus 로고    scopus 로고
    • Defining the competencies of those conducting pharmacovigilance
    • DOI: 10.1002/pds.1153
    • Edwards B, Tilson H, West S. Defining the competencies of those conducting pharmacovigilance. Pharmacoepidemiol Drug Saf 2006; 15: 193-198. DOI: 10.1002/pds.1153
    • (2006) Pharmacoepidemiol Drug Saf , vol.15 , pp. 193-198
    • Edwards, B.1    Tilson, H.2    West, S.3
  • 12
    • 23044447801 scopus 로고    scopus 로고
    • Opening Pandora's Pillbox: Using modern information tools to improve drug safety
    • DOI: 10.1377/hlthaff.24.4.938
    • Gottlieb S. Opening Pandora's Pillbox: using modern information tools to improve drug safety. Health Aff 2005; 24: 938-948. DOI: 10.1377/hlthaff.24.4.938
    • (2005) Health Aff , vol.24 , pp. 938-948
    • Gottlieb, S.1
  • 14
    • 39749199590 scopus 로고    scopus 로고
    • The Henry J. Kaiser Family Foundation. FDA to release list of projects to reduce rx appmval times, 15 March 2006, http://www.kaisernetwork.org/daily_reports/print_report.cfm?DR_ID= 36031&drť=3 (15 March 2006).
    • The Henry J. Kaiser Family Foundation. FDA to release list of projects to reduce rx appmval times, 15 March 2006, http://www.kaisernetwork.org/daily_reports/print_report.cfm?DR_ID= 36031&drť=3 (15 March 2006).
  • 15
    • 25444458574 scopus 로고    scopus 로고
    • Kramer JM. Managing the risks of therapeutic products: proceedings of a workshop. Pharmacoepidemiol Drug Saf 2005; 14: 619-628. DOI: 10.1002/pds.1060
    • Kramer JM. Managing the risks of therapeutic products: proceedings of a workshop. Pharmacoepidemiol Drug Saf 2005; 14: 619-628. DOI: 10.1002/pds.1060


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.